|
| ||||||||||||||
MannKind Keeps the Faith in Inhaled Insulin With Opening of $114 Million Production Plant in Connecticut, an Industrial Info News Alert SUGAR LAND, TX--(MARKET WIRE)--Sep 17, 2008 -- Reported by Annette Kreuger, Industrial Info
Resources (Sugar Land, Texas) -- The MannKind Corporation
(MNKD - News)
(Valencia, California) will unveil its new $114 million
insulin system
production plant in Danbury, Connecticut, today. Construction
began last
year on the project, which will produce, package and distribute
the
company's Technosphere insulin and inhaler. Earlier this
year, Eli Lilly &
Company (LLY - News) (Indianapolis, Indiana), Novo Nordisk
(NVO - News)
(Bagsvaerd, Denmark) and Pfizer Incorporated (PFE - News)
(New York, New
York) all abandoned similar products that were designed
to replace
injections for people suffering from diabetes. MannKind,
founded in 1991 by
billionaire Alfred Mann, has firmly stayed the course with
its development
of the controversial product. For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=138928, or browse other breaking industrial news stories at www.industrialinfo.com. Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com. Related News Articles From Boston to Beijing: Massachusetts Expands Biotech Trade Efforts in China Contact: Contact:
Joe Govreau
713-783-5147
Source: Industrial Info Resources
|  | |||||||||||||
